John Wagner, M.D., Ph.D., Dr. Wagner received his M.D. from Stanford University School of Medicine and Ph.D. from the Johns Hopkins University School of Medicine. Postgraduate training included Internal Medicine Internship and Residency, as well as Molecular and Clinical Pharmacology Postdoctoral Fellowships at Stanford. He began his professional career in academic research on Cystic Fibrosis and has continued in the pharmaceutical industry, largely in the context of drug development as well as biomarkers. Currently, Dr. Wagner is Senior Vice President and Head, Clinical and Translational Sciences, Takeda Pharmaceutical International. He is also President, the American Society for Clinical Pharmacology and Therapeutics (ASCPT), a premier translational medicine and clinical pharmacology scientific association in the US. Dr. Wagner is also on the adjunct faculty at Harvard - Massachusetts Institute of Technology. Previously, he was Senior Consultant to the Institute of Medicine, Vice President and Head, Early Development Pipeline and Projects and Head, Global Project Management at Merck & Co., Inc., co-chair of Merck’s early development governance committee, Vice President and Head, Clinical Pharmacology, at Merck & Co., Inc and Acting Modeling and Simulation Integrator, Strategically Integrated Modeling and Simulation. He is the past chair of the PhRMA Clinical Pharmacology Technical Group, past chair of the adiponectin work group for the Biomarkers Consortium, past committee member of the National Academies Institute of Medicine Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, and current full member of the National Academies Institute of Medicine National Cancer Policy Forum. Over 200 peer-reviewed publications detail work across a variety of therapeutic areas and disciplines.